Search

Oportuzumab monatox

VB4-845 is a fusion protein containing humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM, a tumor cell-associated target highly expressed on carcinoma cells of epithelial origin … VB4-845 is studied in the treatment of certain types of head and neck cancer. VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells.

Alkaline Phosphatase

AP only acts locally in the colon to reduce the continuous inflammation of the colon by endotoxin from Gram-negative bacteria and extracellular ATP in UC patients. … Alkaline Phosphatase (AP) is an oral treatment and has a very favorable side-effect profile.

Lobeglitazone

Lobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes. … Lobeglitazone is an antidiabetic medication from the thiazolidinedione class of drugs.

Aleglitazar

Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. … In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects

Hemin

Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand.

Sulopenem etzadroxil

[L51858] It is administered in combination with [probenecid] in order to increase antibiotic exposure.[L51768] … [L51768] Sulopenem etzadroxil was approved by the FDA in October 2024 for the treatment of uncomplicated urinary tract infections.

N-Acetylglucosamine

The N-acetyl derivative of glucosamine.

Varespladib methyl

Studies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.

Iofetamine I-123

Urethane

Urethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.